Hunan Hansen Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

De CEO Hunan Hansen Pharmaceutical is Zhengqing Liu, benoemd in Jan2008, heeft een ambtstermijn van 16.83 jaar. bezit rechtstreeks 1.42% van de aandelen van het bedrijf, ter waarde CN¥ 45.05M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.5 jaar en 4.5 jaar.

Belangrijke informatie

Zhengqing Liu

Algemeen directeur

CN¥1.7m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	16.8yrs
Eigendom CEO	1.4%
Management gemiddelde ambtstermijn	4.5yrs
Gemiddelde ambtstermijn bestuur	4.5yrs

Recente managementupdates

Recent updates

Hunan Hansen Pharmaceutical Co., Ltd.'s (SZSE:002412) Shares Lagging The Market But So Is The Business

Sep 30

CEO

Zhengqing Liu (60 yo)

16.8yrs

Tenure

CN¥1,675,700

Compensatie

Mr. Zhengqing Liu has been Chief Executive Officer and Non-Independent Director of Hunan Hansen Pharmaceutical Co., Ltd. since January 20, 2008 and serves as its Chairman since May 25, 2020.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Zhengqing Liu	Chairman & CEO	16.8yrs	CN¥1.68m	1.42% CN¥ 45.1m
Jianghong Dai	VP, CFO & Board Secretary	4.5yrs	CN¥284.60k	geen gegevens
Hua Yang	VP & MD of Hansen Research	3.9yrs	CN¥324.60k	geen gegevens
Lingsong Ao	Director & VP	4.4yrs	CN¥888.20k	geen gegevens
Jianjun Fu	Director & VP	4.4yrs	CN¥328.20k	geen gegevens
Ai Hua Liu	Vice President	13.7yrs	CN¥311.70k	geen gegevens

4.5yrs

Gemiddelde duur

53.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002412 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zhengqing Liu	Chairman & CEO	16.8yrs	CN¥1.68m	1.42% CN¥ 45.1m
Lingsong Ao	Director & VP	4.4yrs	CN¥888.20k	geen gegevens
Jianjun Fu	Director & VP	4.4yrs	CN¥328.20k	geen gegevens
Renhui Fu	Supervisor	13.7yrs	geen gegevens	geen gegevens
Ping Zhan	Independent Director	4.5yrs	CN¥70.00k	geen gegevens
Jinsong Xia	Independent Director	4.5yrs	CN¥70.00k	geen gegevens
Gaoyun Hu	Independent Director	4.5yrs	CN¥70.00k	geen gegevens
Bingyang Liu	Non-Independent Director	1.5yrs	geen gegevens	geen gegevens
Chen Chen	Shareholder Supervisor	1.5yrs	geen gegevens	geen gegevens

4.5yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002412 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).

Hunan Hansen Pharmaceutical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 23, 2023

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.06 (vs CN¥0.038 in 3Q 2023)

Hunan Hansen Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 20%

Hunan Hansen Pharmaceutical Co., Ltd.'s (SZSE:002412) Shares Lagging The Market But So Is The Business

Second quarter 2024 earnings released: EPS: CN¥0.084 (vs CN¥0.071 in 2Q 2023)

Hunan Hansen Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 14, 2024

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 1Q 2023)

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Investor sentiment deteriorates as stock falls 15%

Now 22% undervalued after recent price drop

Hunan Hansen Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Now 25% undervalued after recent price drop

Now 27% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 18%

Hunan Hansen Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Second quarter 2023 earnings released: EPS: CN¥0.071 (vs CN¥0.054 in 2Q 2022)

Hunan Hansen Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on June 20, 2023

Insufficient new directors

Hunan Hansen Pharmaceutical Co., Ltd., Annual General Meeting, May 23, 2023

Full year 2022 earnings released: EPS: CN¥0.33 (vs CN¥0.27 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.085 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.054 (vs CN¥0.05 in 2Q 2021)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

Now 24% undervalued

Now 21% undervalued

Now 23% undervalued

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.085 (vs CN¥0.063 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.05 (vs CN¥0.032 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.091 (vs CN¥0.073 in 1Q 2020)

New 90-day low: CN¥5.78

New 90-day low: CN¥6.17

New 90-day high: CN¥7.46

New 90-day low: CN¥6.66

Third quarter earnings released

Hunan Hansen Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥6.77

First half earnings released

New 90-day high - CN¥8.17

Hunan Hansen Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd